Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Endocyte Inc (NASDAQ:ECYT)

3.29
Delayed Data
As of Jun 24
 -0.23 / -6.53%
Today’s Change
2.65
Today|||52-Week Range
5.87
-17.96%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$139.5M

Company Description

Endocyte, Inc. is a biopharmaceutical company, which develops targeted therapies for the treatment of cancer and inflammatory diseases. The company uses its proprietary technology to create novel small molecule drug conjugates and companion imaging diagnostics for personalized targeted therapies. Its small molecule drug conjugates are actively target receptors that are over-expressed on diseased cells. The company was founded by P. Ron Ellis and Philip S. Low on December 6, 1995 and is headquartered in West Lafayette, IN.

Contact Information

Endocyte, Inc.
3000 Kent Avenue
West Lafayette Indiana 47906
P:(765) 463-7175
Investor Relations:

Employees

Shareholders

Individual stakeholders22.09%
Other institutional20.50%
Mutual fund holders18.39%

Top Executives

Michael A. ShermanPresident, CEO, CFO & Director
Philip S. LowDirector & Chief Science Officer
Christopher P. LeamonVice President-Research & Development
Scot L. HarperVice President-Clinical Operations
Alison A. ArmourChief Medical Officer